{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:23:56Z","timestamp":1777047836381,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Business and Decision Life Sciences, Belgium"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.04.058","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T08:45:14Z","timestamp":1493455514000},"page":"3041-3049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Challenges in conducting post-authorisation safety studies (PASS): A vaccine manufacturer's view"],"prefix":"10.1016","volume":"35","author":[{"given":"Catherine","family":"Cohet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Rosillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Willame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Haguinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-No\u00eblle","family":"Marenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Buyse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Bauchau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Baril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2017.04.058_b0005","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1586\/14760584.2015.1091733","article-title":"The costs and effectiveness of large phase III pre-licensure vaccine clinical trials","volume":"14","author":"Black","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2017.04.058_b0010","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/21645515.2015.1043501","article-title":"Safety assessment of adjuvanted vaccines: methodological considerations","volume":"11","author":"Tavares Da Silva","year":"2015","journal-title":"Hum Vac Immunother"},{"key":"10.1016\/j.vaccine.2017.04.058_b0015","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VIII \u2013 Post-authorisation safety studies (Rev 1), EMA\/813938\/2011 Rev 2 2016. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129137.pdf. [Accessed 2017 April 7]."},{"key":"10.1016\/j.vaccine.2017.04.058_b0020","unstructured":"European Medicines Agency. European Medicines Agency process for engaging in external regulatory sciences and process improvement research activities for public and animal health. EMA\/14946\/2013. Patient Health Protection 2013. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2013\/03\/WC500139888.pdf. [Accessed 2017 April 7]."},{"key":"10.1016\/j.vaccine.2017.04.058_b0025","unstructured":"European Medicines Agency. Committee for Human Medicinal Products. Note for guidance on the clinical evaluation of vaccines. CHMP\/VWP\/164653\/2005 2005. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003875.pdf. [Accessed 2017 April 7]."},{"issue":"5","key":"10.1016\/j.vaccine.2017.04.058_b0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd3713-c1","article-title":"Proactively managing the risk of marketed drugs: experience with the EMA pharmacovigilance risk assessment committee","volume":"13","author":"Arlett","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.vaccine.2017.04.058_b0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP)","volume":"25","author":"Public Policy Committee International Society of Pharmacoepidemiology","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2017.04.058_b0040","unstructured":"Food and Drug Administration and Center for Biologics Evaluation and Research. Center for Biologics Evaluation and Research. Guidance for Industry Postmarketing Studies and Clinical Trials \u2014 Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act 2011. Available from: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm172001.pdf. [Accessed 2017 April 7]."},{"issue":"43","key":"10.1016\/j.vaccine.2017.04.058_b0045","first-page":"1007","article-title":"Withdrawal of rotavirus vaccine recommendation","volume":"48","author":"Centers for disease control and prevention","year":"1999","journal-title":"Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2017.04.058_b0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis","volume":"354","author":"Ruiz-Palacios","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2017.04.058_b0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.vaccine.2009.10.041","article-title":"RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe","volume":"28","author":"Vesikari","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2017.04.058_b0060","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/INF.0b013e318253add3","article-title":"Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico","volume":"31","author":"Vel\u00e1zquez","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.04.058_b0065","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ofid\/ofw172.660","article-title":"Intussusception and mortality after vaccination with live, oral, human rotavirus vaccine: a cohort study in United States health insurance plans","volume":"3","author":"Hoffman","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2017.04.058_b0070","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/INF.0000000000000715","article-title":"Risk of intussusception after rotavirus vaccination: meta-analysis of postlicensure studies","volume":"34","author":"Rosillon","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2017.04.058_b0075","first-page":"1306","article-title":"Risk of intussusception after rotavirus vaccination: a meta-analysis","volume":"9","author":"Dong","year":"2016","journal-title":"Int J Clin Exp Med"},{"issue":"29","key":"10.1016\/j.vaccine.2017.04.058_b0080","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1016\/j.vaccine.2014.04.082","article-title":"Evaluating the potential risks and benefits of infant rotavirus vaccination in England","volume":"32","author":"Clark","year":"2014","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.vaccine.2017.04.058_b0085","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1016\/j.vaccine.2009.07.076","article-title":"A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile","volume":"27","author":"Czajka","year":"2009","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.vaccine.2017.04.058_b0090","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","article-title":"Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting","volume":"27","author":"Jacobsen","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2017.04.058_b0095","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.vaccine.2013.12.011","article-title":"Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination","volume":"32","author":"Schink","year":"2014","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2017.04.058_b0100","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s40264-015-0326-4","article-title":"Modelling hospitalisation ratios for febrile convulsions and severe varicella under combined measles, mumps, rubella, and varicella (MMRV-Priorix-Tetra\u2122) compared to separate MMR+V vaccination","volume":"38","author":"Bauchau","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2017.04.058_b0105","doi-asserted-by":"crossref","first-page":"c712","DOI":"10.1136\/bmj.c712","article-title":"Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials","volume":"340","author":"Wacholder","year":"2010","journal-title":"BMJ"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2017.04.058_b0110","first-page":"S358","article-title":"Challenges and design of a prospective, observational cohort study to assess the risk of spontaneous abortion following administration of human papillomavirus (HPV) bivalent (Types 16 and 18) recombinant vaccine","volume":"20","author":"Chambers","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.vaccine.2017.04.058_b0115","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: clinical practice research datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"48","key":"10.1016\/j.vaccine.2017.04.058_b0120","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1016\/j.vaccine.2015.07.024","article-title":"Risk of spontaneous abortion and other pregnancy outcomes in 15\u201325 year old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"33","author":"Baril","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.058_b0125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.phrs.2015.08.003","article-title":"Vaccines, adjuvants and autoimmunity","volume":"100","author":"Guimar\u00e3es","year":"2015","journal-title":"Pharmacol Res"},{"issue":"14","key":"10.1016\/j.vaccine.2017.04.058_b0130","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","article-title":"Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines","volume":"31","author":"Tavares Da Silva","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2017.04.058_b0135","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.4161\/hv.21268","article-title":"Evaluation of autoimmune safety signal in observational vaccine safety studies","volume":"8","author":"Chao","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2017.04.058_b0140","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/21645515.2016.1199308","article-title":"Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"12","author":"Willame","year":"2016","journal-title":"Hum Vac Immunother"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2017.04.058_b0145","first-page":"474","article-title":"Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France","volume":"25","author":"Chaignot","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2017.04.058_b0150","unstructured":"European network of centres for pharmacoepidemiology and pharmacovigilance. Study 205639 \u2013 Meta-analysis of the risk of autoimmune thyroiditis diseases, Guillain-Barr\u00e9 Syndrome, and inflammatory bowel disease with cervarix vaccination. Available from: http:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=13652. [Accessed 2017 April 7]."},{"issue":"10","key":"10.1016\/j.vaccine.2017.04.058_b0155","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.4161\/21645515.2014.972149","article-title":"Safety of AS03-adjuvanted inactivated split virion A(H1N1) pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials","volume":"10","author":"Vaughn","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.058_b0160","unstructured":"European medicines agency. CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine. Revision 1.1. EMEA\/359381\/2009 2009. Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/01\/WC500051739.pdf. [Accessed 2017 April 7]."},{"issue":"2","key":"10.1016\/j.vaccine.2017.04.058_b0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001912","article-title":"Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study","volume":"3","author":"Nazareth","year":"2013","journal-title":"BMJ Open"},{"issue":"37","key":"10.1016\/j.vaccine.2017.04.058_b0170","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1016\/j.vaccine.2011.04.114","article-title":"Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study","volume":"29","author":"Tavares","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.058_b0175","unstructured":"Baril L, Pircon J, Bozonnat M, et al., Designing epidemiological studies for the post approval plan of the RTS, S\/AS01 malaria vaccine in sub-Saharan African countries. Malaria Vaccines for the World, 2\u20134 May 2016, Leiden, The Netherlands. 2016 2016\/05\/02\/4. Malaria Vaccines for the World, 2\u20134 May 2016, Leiden, The Netherlands: Publisher."},{"key":"10.1016\/j.vaccine.2017.04.058_b0180","unstructured":"ClincalTrials.gov. A surveillance study of diseases specified as adverse events of specific interest (AESI) and serious adverse events (SAEs) in children in africa prior to implementation of the RTS,S\/AS01E candidate vaccine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02374450. [Accessed 2017 April 7]."},{"issue":"1","key":"10.1016\/j.vaccine.2017.04.058_b0185","doi-asserted-by":"crossref","first-page":"e009264","DOI":"10.1136\/bmjopen-2015-009264","article-title":"Effect of the adjuvanted (AS03) A\/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series","volume":"6","author":"Cohet","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2017.04.058_b0190","doi-asserted-by":"crossref","DOI":"10.1007\/s40264-017-0532-3","article-title":"Adjuvanted (AS03) A\/H1N1 2009 pandemic influenza vaccines and solid organ transplant rejection: systematic signal evaluation and lessons learnt","author":"Dos Santos","year":"2017","journal-title":"Drug Saf"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2017.04.058_b0195","doi-asserted-by":"crossref","first-page":"B6","DOI":"10.1016\/j.vaccine.2015.03.026","article-title":"The narcolepsy-pandemic influenza story: can the truth ever be unraveled?","volume":"33","author":"Sturkenboom","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2017.04.058_b0200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/21645515.2015.1068486","article-title":"Pandemrix\u2122 and narcolepsy: a critical appraisal of the observational studies","volume":"12","author":"Verstraeten","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.vaccine.2017.04.058_b0205","doi-asserted-by":"crossref","first-page":"e108489","DOI":"10.1371\/journal.pone.0108489","article-title":"Risk of narcolepsy associated with inactivated adjuvanted (AS03) A\/H1N1 (2009) pandemic influenza vaccine in Quebec","volume":"9","author":"Montplaisir","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.058_b0210","first-page":"406","article-title":"Applying the Test-Negative Design to Vaccine Safety Studies: Risk of Narcolepsy Associated with A\/H1N1 (2009) Pandemic Influenza Vaccination in Quebec","volume":"vol. 24","author":"Cohet","year":"2015"},{"issue":"1","key":"10.1016\/j.vaccine.2017.04.058_b0215","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.vaccine.2012.07.024","article-title":"Biologically plausible and evidence-based risk intervals in immunization safety research","volume":"31","author":"Rowhani-Rahbar","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.058_b0220","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CLEP.S104448","article-title":"Helping everyone do better: a call for validation studies of routinely recorded health data","volume":"8","author":"Ehrenstein","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.04.058_b0225","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/pds.4081","article-title":"Importance of feasibility assessments before implementing non-interventional pharmacoepidemiological studies of vaccines: lessons learned and recommendations for future studies","volume":"25","author":"Willame","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.vaccine.2017.04.058_b0230","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.biologicals.2012.07.007","article-title":"Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe","volume":"40","author":"Bonhoeffer","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2017.04.058_b0235","first-page":"12","article-title":"Public-private collaboration to advance the development and benefit-risk assessment of vaccines: the innovative medicines initiative","volume":"2","author":"Wittelsberger","year":"2014","journal-title":"JHPOR"},{"issue":"15","key":"10.1016\/j.vaccine.2017.04.058_b0240","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.vaccine.2017.02.039","article-title":"The ADVANCE code of conduct for collaborative vaccine studies","volume":"35","author":"Kurz","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.058_b0245","unstructured":"European medicines agency. pharmacovigilance \u2013 pharmacovigilance legislation 2012. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000491.jsp. [Accessed 2017 April 7]."},{"key":"10.1016\/j.vaccine.2017.04.058_b0250","series-title":"Volume 9A of the rules governing medicinal products in the european union \u2013 guidelines on pharmacovigilance for medicinal products for human use (2008)","author":"EudraLex EU Legislation - European Commission","year":"2008"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T10:02:50Z","timestamp":1569146570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17305509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":50,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X17305509"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in conducting post-authorisation safety studies (PASS): A vaccine manufacturer's view","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 GSK Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}